NeuroBo Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-15.64 Insider Own0.10% Shs Outstand6.50M Perf Week2.61%
Market Cap7.52M Forward P/E- EPS next Y-0.70 Insider Trans0.00% Shs Float6.04M Perf Month-77.57%
Income-13.90M PEG- EPS next Q-0.15 Inst Own3.30% Short Float / Ratio27.24% / 0.55 Perf Quarter-82.89%
Sales- P/S- EPS this Y63.90% Inst Trans-30.08% Short Interest1.65M Perf Half Y-88.23%
Book/sh6.68 P/B0.24 EPS next Y-4.50% ROA-115.80% Target Price- Perf Year-96.49%
Cash/sh1.34 P/C1.18 EPS next 5Y- ROE-134.30% 52W Range1.13 - 63.85 Perf YTD-95.71%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-97.54% Beta-0.16
Dividend %- Quick Ratio4.70 Sales past 5Y- Gross Margin- 52W Low38.94% ATR0.54
Employees5 Current Ratio4.70 Sales Q/Q- Oper. Margin- RSI (14)32.26 Volatility13.24% 18.88%
OptionableYes Debt/Eq0.00 EPS Q/Q24.80% Profit Margin- Rel Volume0.53 Prev Close1.43
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume2.98M Price1.57
Recom2.00 SMA20-5.45% SMA50-79.54% SMA200-89.70% Volume1,566,295 Change9.79%
Jun-15-20Initiated H.C. Wainwright Buy $20
Nov-08-22 04:05PM
Nov-04-22 09:15AM
Sep-29-22 08:30AM
Sep-15-22 08:30AM
Sep-12-22 09:15AM
08:00AM Loading…
May-06-22 08:00AM
Apr-01-22 08:00AM
Mar-15-22 08:00AM
Jan-28-22 04:30PM
Nov-15-21 08:00AM
Nov-04-21 08:00AM
Oct-13-21 08:00AM
Oct-05-21 01:13PM
Oct-01-21 08:00AM
Sep-03-21 11:27AM
08:00AM Loading…
Aug-16-21 08:00AM
Jul-12-21 08:30AM
May-17-21 05:02PM
Apr-15-21 04:52PM
Mar-24-21 08:00AM
Mar-05-21 08:30AM
Jan-21-21 04:05PM
Jan-19-21 08:00AM
Jan-06-21 08:30AM
Dec-21-20 05:08AM
Nov-13-20 04:30PM
Sep-02-20 08:30AM
Aug-11-20 03:00PM
Jun-16-20 04:05PM
May-26-20 08:30AM
04:29PM Loading…
May-20-20 04:29PM
Apr-21-20 08:30AM
Apr-16-20 04:22PM
Apr-14-20 09:15AM
Mar-31-20 11:04AM
Mar-30-20 04:30PM
Jan-13-20 09:00AM
Jan-10-20 05:00PM
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. It develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.